A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT ID: NCT05744401
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
198 participants
INTERVENTIONAL
2023-01-04
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
NCT04592874
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
A Phase I Study for Safety and Tolerability of AL002.
NCT03635047
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
NCT02220738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AL002 Dose 1
AL002 every 4 weeks
AL002
Administered via intravenous (IV) infusion
AL002 Dose 2
AL002 every 4 weeks
AL002
Administered via intravenous (IV) infusion
AL002 Dose 3
AL002 every 4 weeks
AL002
Administered via intravenous (IV) infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AL002
Administered via intravenous (IV) infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant is willing and able to give informed consent.
* Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week
Exclusion Criteria
* Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons.
* Participation deemed inappropriate per Investigator discretion.
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Alector Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
TBD TBD
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
SFM Clinical Research, LLC
Boca Raton, Florida, United States
Charter Research
Lady Lake, Florida, United States
K2 Medical Research - Maitland
Maitland, Florida, United States
Progressive Medical Research - ClinEdge - PPDS
Port Orange, Florida, United States
Axiom Brain Health LLC
Tampa, Florida, United States
"Alzheimers Research and Treatment Center-Wellington "
Wellington, Florida, United States
Conquest Research LLC - Winter Park - ClinEdge - PPDS
Winter Park, Florida, United States
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
Advanced Clinical Institute
Neptune City, New Jersey, United States
Feinstein Institute For Medical Research
Manhasset, New York, United States
SUNY Upstate Medical Center
Syracuse, New York, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Summit Research Network
Portland, Oregon, United States
Instituto Privado Kremer
Córdoba, Córdoba Province, Argentina
Centro de Psiquiatria Biologica
Mendoza, , Argentina
KaRa Institute of Neurological Disease
Macquarie Park, New South Wales, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Kawartha Regional Memory Clinic
Peterborough, Ontario, Canada
Baycrest Health Sciences
Toronto, Ontario, Canada
Universitätsklinikum Ulm-Oberer Eselsberg 45
Ulm, Baden-Wurttemberg, Germany
Klinikum rechts der Isar der Technischen Universitaet Muenchen
Munich, Bavaria, Germany
Ambulantes Gesundheitszebtrum der Charite GmbH
Berlin, , Germany
Charité - Universitätsmedizin Berlin
Berlin, , Germany
Fondazione Policlinico Universitario A Gemelli-Rome
Rome, Lazio, Italy
Azienda Policlinico Umberto
Rome, Lazio, Italy
Ospedale Isola Tiberina - Gemelli Isola
Rome, Lazio, Italy
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN
Brescia, Lombardy, Italy
IRCCS - Centro S. Giovanni di Dio Fatebene fratelli
Brescia, Lombardy, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
Milan, Lombardy, Italy
ASL Biella - Ospedale degli Infermi
Ponderano, Piedmont, Italy
Azienda Ospedaliero-Universitaria di Modena - Policlinico di Modena
Modena, , Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Brain Research Center Den Bosch - PPDS
's-Hertogenbosch, North Brabant, Netherlands
NZOZ Wroclawskie Centrum Alzheimerowskie
Wroclaw, Lower Silesian Voivodeship, Poland
Centrum Medyczne NeuroProtect
Warsaw, Masovian Voivodeship, Poland
EUROMEDIS Sp. z o.o.
Szczecin, West Pomeranian Voivodeship, Poland
Fundacion CITA Alzheimer Fundazioa
San Sebastián, Guipúzcoa, Spain
Centro De Atencion Especializada Oroitu
Getxo, Vizcaya, Spain
Hospital de La Santa Creu i Sant Pau
Barcelona, , Spain
Fundacion ACE Instituto Catalan de Neurociencias-Gran via de Carles III, 85 bis
Barcelona, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Universitario Doctor Peset
Valencia, , Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, , Spain
Hospital Viamed Montecanal
Zaragoza, , Spain
RE: Cognition Health - Plymouth
Plymouth, Devon, United Kingdom
Re:Cognition Health - Guildford - PPDS
Guildford, Surrey, United Kingdom
Re-Cognition Health - Bristol
Bristol, , United Kingdom
Re:Cognition Health
London, , United Kingdom
The National Hospital for Neurology and Neurosurgery
London, , United Kingdom
NeuroClin Glasgow
Motherwell, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL002-LTE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.